Methylethyltryptamine

Template:Short description Template:Cs1 config Template:Main other Template:Template other{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type= | _number_of_combo_chemicals= | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=13182c1cccc2c1c(c[nH]2)CCN(CC)C1S/C13H18N2/c1-3-15(2)9-8-11-10-14-13-7-5-4-6-12(11)13/h4-7,10,14H,3,8-9H2,1-2H3MYEGVMLMDWYPOA-UHFFFAOYSA-NTemplate:StdinchiciteTemplate:Stdinchicite | _combo_data= | _physiological_data= | _clinical_data= Oral; Vaporized/inhaledSerotonergic psychedelic; Hallucinogen; Serotonin 5-HT_2A and 5-HT_2C receptor agonist; Serotonin releasing agent | _legal_data=

| _other_data=N-ethyl-2-(1H-indol-3-yl)-N-methylethan-1-amine

| _image_0_or_2 = MET image.svg | _image_LR =

| _datapage = Methylethyltryptamine (data page) | _vaccine_target=_type_not_vaccine | _legal_all= | _ATC_prefix_supplemental= | _has_EMA_link = | CAS_number=5599-69-9 | PubChem=824845 | ChemSpiderID=720502 | ChEBI= | ChEMBL= | DrugBank= | KEGG= | _hasInChI_or_Key=yes | UNII=4KX1J1D3RD | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =

| _countSecondIDs= | _countIndexlabels= | _trackListSortletter= |QID = |QID2 = |Verifiedfields= |Watchedfields= |verifiedrevid=400309782}}

Methylethyltryptamine (MET), also known as N-methyl-N-ethyltryptamine (N,N-MET), is a serotonergic psychedelic of the tryptamine family. It is closely related to dimethyltryptamine (DMT) and to diethyltryptamine (DET). The drug acts as an agonist of the serotonin 5-HT₂ receptors and to a lesser extent as a serotonin releasing agent. It was encountered as a novel designer drug in Europe in 2014.

Use and effects

MET has been briefly mentioned in Alexander Shulgin's TiHKAL (Tryptamines I Have Known and Loved) and other publications, where he has stated it to be orally active as a psychedelic at doses of 80 to 100Template:Nbspmg. The freebase of MET is active as a psychedelic via vaporization at a dose of 15Template:Nbspmg per a 2011 Erowid trip report.

Pharmacology

MET is a serotonin 5-HT_2A and 5-HT_2C receptor partial agonist. It shows very weak activity as an agonist of the serotonin 5-HT_1A and 5-HT_2B receptors. In addition to acting at the serotonin 5-HT₂ receptors, MET is a serotonin releasing agent with lower potency. It produces the head-twitch response, a behavioral proxy of psychedelic effects, in animals.

Chemistry

MET, also known as N-methyl-N-ethyltryptamine, is a substituted tryptamine derivative. It is closely related to N,N-dimethyltryptamine (DMT) and to other N,N-dialkylated tryptamines.

Analogues of MET besides DMT include DET, DPT, DiPT, DBT, MiPT, MBT, EPT, EiPT, and PiPT, among others. Derivatives of MET include 4-HO-MET, 5-MeO-MET, 5-fluoro-MET, and 7-F-5-MeO-MET.

The lysergamide counterpart of MET is ETH-LAD, an analogue of LSD that was first developed and characterized by Alexander Shulgin.

History

MET appears to have first been described in the literature by 1981. It was specifically mentioned in Michael Valentine Smith's Psychedelic Chemistry. Subsequently, MET was briefly described in Alexander Shulgin's TiHKAL (Tryptamines I Have Known and Loved) in 1997. MET was encountered as a novel designer drug in Europe in 2014.

See also

• Bretisilocin (5-fluoro-MET; GM-2505)

External links

• MET - Isomer Design
• MET - Psychonaut Wiki
• MET - Erowid
• The Big & Dandy MET Thread - Bluelight
• MET scraps - Bluelight